PharmaMar comes from a very poor 2025 on the stock market, which ended with a fall of 5.20%, but this year it has already recovered 4.4% of lost ground. and the Santander Group analysts They are optimistic regarding the pharmaceutical company’s stock market future.
Specifically, they have initiated coverage of PharmaMar with an ‘overweight’ advice and a price target of 102 euros which represents a upside potential of 30.9% compared to yesterday’s closing, Thursday.
In this way, Santander stands as one of the most optimistic analysis houses about the future of the PharmaMar Stock Market, taking into account that the majority recommendation that its shares receive is ‘keep‘, according to data collected by Reuters. The average target price scales at 97,99 euros per share, 25.30% above of the current quote.
Today PharmaMar shares rise a slight 0.39% in the Continuous Market to reach 78.20 euros. They have rebounded 20.30% since they set a 52-week low of 65 euros in April last year, but they are still falling 26% from their highs of the same period, set at 105.80 euros since March 3.
PharmaMar managed to double its net profit in the first nine months of 2025, reaching 15.3 million euros. Revenue increased by 3% to 130.9 million euros, while EBITDA was 23.1 million, up 272%.